May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
VEGF 165 Serum Levels Following Systemic Bevacizumab (Avastin®) Therapy for Neovascular Age–Related Macular Degeneration
Author Affiliations & Notes
  • A.M. Rosin
    Ophthalmology, Medical University Vienna, Vienna, Austria
  • S. Michels
    Ophthalmology, Medical University Vienna, Vienna, Austria
  • W. Geitzenauer
    Ophthalmology, Medical University Vienna, Vienna, Austria
  • F. Prager
    Ophthalmology, Medical University Vienna, Vienna, Austria
  • U. Schmidt–Erfurth
    Ophthalmology, Medical University Vienna, Vienna, Austria
  • Footnotes
    Commercial Relationships  A.M. Rosin, None; S. Michels, None; W. Geitzenauer, None; F. Prager, None; U. Schmidt–Erfurth, None.
  • Footnotes
    Support  German Research Foundation MI 742
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 2173. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A.M. Rosin, S. Michels, W. Geitzenauer, F. Prager, U. Schmidt–Erfurth; VEGF 165 Serum Levels Following Systemic Bevacizumab (Avastin®) Therapy for Neovascular Age–Related Macular Degeneration . Invest. Ophthalmol. Vis. Sci. 2006;47(13):2173.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To monitor VEGF 165 serum levels in patients with neovascular age–related macular degeneration (AMD) treated with intravenous Bevacizumab (Avastin®).

Methods: : 15 patients received 3 infusions of either 5mg/kg or 2,5mg/kg of bevacizumab at two week intervals. VEGF 165 serum levels were determined by Enzyme–Linked Immunosorbent Assay (ELISA) at baseline and at 1, 2, 3 and 6 months follow–up.

Results: : In every single patient VEGF 165 serum levels were determinable. All patients showed decreased VEGF 165 serum levels after the first bevacizumab infusion. A 50% VEGF 165 serum level reduction was seen after 4 weeks compared to baseline level. The third infusion did not induce a further reduction in VEGF 165 serum levels. VEGF 165 serum levels started rising again at month 3 and reached about baseline levels at month 6.

Conclusions: : Systemic bevacizumab therapy reduced VEGF 165 serum levels for at least 3 months, which may explain the long treatment durability in patients with neovascular AMD. Monitoring VEGF 165 serum levels could become useful tool in monitoring patients at risk for recurrent neovascular AMD and in optimizing the treatment regimen.

Keywords: age-related macular degeneration • growth factors/growth factor receptors • clinical laboratory testing 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×